

### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

#### Patent Claims

- 1). (Previously Presented) A cholesterol-reducing agent comprising at least one carob product, at least one n-3 fatty acid and at least one cholesterol-reducing active compound, the cholesterol-reducing active compound being selected from one or more of the following substances: statins, inhibitors of bile acid resorption, cholesterol absorption inhibitors, fibrates, nicotinic acid derivatives, bile acid sequestrants, phytosterols, plant stanols and also cholesterol-reducing plant extracts.
- 2). (Original) The agent as claimed in claim 1, wherein the carob product is carob fruit flesh or a product produced from carob fruit flesh.
- 3). (Original) The agent as claimed in claim 1, wherein the carob product is carob fiber.
- 4). (Original) The agent as claimed in claim 3, wherein the carob fiber is insoluble in water.
- 5). (Currently Amended) The agent as claimed in ~~one of claim~~[[s]] 1 ~~to~~ 4, wherein the n-3 fatty acid is a polyunsaturated fatty acid having a chain length > C12 having at least two double bonds, or its ester, triglyceride, phospholipid, glycolipid, sphingolipid, wax or sterol ester.
- 6). (Original) The agent as claimed in claim 5, wherein the first of the at least two double bonds starting from the alkyl end is constituted between the carbon atoms C3 and C4.

7). (Currently Amended) The agent as claimed in claim 5 ~~or~~ 6, wherein the n-3 fatty acid is selected from one or more of the following substances: all-cis-9,12,15-octadecatrienoic acid (ALA), all-cis-6,9,12,15-octadecatetraenoic acid, all-cis-11,14,17-eicosatrienoic acid, all-cis-8,11,14,17-eicosatetraenoic acid, all-cis-5,8,11,14,17-eicosapentaenoic acid (EPA), all-cis-13,16,19-docosatrienoic acid, all-cis-7,10,13,16,19-docosapentaenoic acid (DPA) and all-cis-4,7,10,13,16,19-docosahexaenoic acid (DHA).

8). (Original) The agent as claimed in claim 7, wherein the n-3 fatty acid is all-cis-4,7,10,13,16,19-docosahexaenoic acid (DHA).

9). (Currently Amended) The agent as claimed in ~~one of~~ claim[[s]] 5 ~~to~~ 8, wherein the n-3 fatty acid is not derivatized.

10). (Previously Presented) A cholesterol-reducing combination preparation comprising at least one carob product, at least one n-3 fatty acid and at least one cholesterol-reducing active compound in separate administration forms.

11). (Previously Presented) The cholesterol-reducing combination preparation as claimed in claim 10, in which the carob product and the n-3 fatty acid are present in a food.

12). (Previously Presented) The cholesterol-reducing combination preparation as claimed in claim 10, in which the active compound is present in a food or a drug.

13). (Currently Amended) A method for producing an agent as claimed in ~~one of~~ claim[[s]] 1 ~~to~~ 9, which comprises mixing at least one carob product and at least one n-3 fatty acid and at least one cholesterol-reducing active compound with one another.

14). (Currently Amended) ~~The use of~~ A drug comprising an agent as claimed in ~~one of~~ claim[[s]] 1 ~~to~~ 9 ~~as drug~~.

15). (Currently Amended) ~~The use~~ A drug as claimed in claim 11 ~~as~~ wherein said drug is a cholesterol-reducing drug.

16). (Currently Amended) ~~The use~~ A drug as claimed in claim 11 wherein said drug is a ~~for~~ the prophylaxis of hypercholesterolemia, hyperlipidemia or arteriosclerosis.

17). (Currently Amended) ~~The use~~ A drug as claimed in claim 11 ~~for the positive~~ said drug positively shifting of the HDL/LDL ratio.

18). (Currently Amended) ~~The use of an~~ An agent as claimed in ~~one of claim~~ claim ~~[[s]] 1 to 9 for~~ said agent further comprising an additional supply ~~with~~ of n-3 fatty acids.

19). (Currently Amended) ~~The use of an agent as claimed in one of claims 1 to 9 for~~ producing pet Pet food comprising an agent as claimed in claim 1 as “heart food” for pets.